These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 18952760)

  • 21. The evolution of fluoropyrimidine therapy: from intravenous to oral.
    Hoff PM; Cassidy J; Schmoll HJ
    Oncologist; 2001; 6 Suppl 4():3-11. PubMed ID: 11585968
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The oral fluorinated pyrimidines.
    de Bono JS; Twelves CJ
    Invest New Drugs; 2001; 19(1):41-59. PubMed ID: 11291832
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PharmGKB summary: fluoropyrimidine pathways.
    Thorn CF; Marsh S; Carrillo MW; McLeod HL; Klein TE; Altman RB
    Pharmacogenet Genomics; 2011 Apr; 21(4):237-42. PubMed ID: 20601926
    [No Abstract]   [Full Text] [Related]  

  • 24. Capecitabine-induced inflammation of actinic keratosis: case report and literature review.
    Stanciu M; Aubut N; Gagné E; Thibeault MM
    J Cutan Med Surg; 2012; 16(5):298-9. PubMed ID: 22971302
    [No Abstract]   [Full Text] [Related]  

  • 25. [Acute coronary syndrome during oral capecitabine monotherapy].
    Martí V; Monell J; Seixo F; Falces C
    Rev Esp Cardiol; 2008 May; 61(5):548-9. PubMed ID: 18462663
    [No Abstract]   [Full Text] [Related]  

  • 26. Rabeprazole intake does not affect systemic exposure to capecitabine and its metabolites, 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, and 5-fluorouracil.
    Sekido M; Fujita KI; Kubota Y; Ishida H; Takahashi T; Ohkuma R; Tsunoda T; Ishikawa F; Shibanuma M; Sasaki Y
    Cancer Chemother Pharmacol; 2019 Jun; 83(6):1127-1135. PubMed ID: 30972456
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Japanese phase I study of continuous oral capecitabine in patients with malignant solid tumors.
    Saeki T; Takashima S; Terashima M; Satoh A; Toi M; Osaki A; Toge T; Ohno S; Nomura N; Fukuyama Y; Koizumi W; Taguchi T
    Int J Clin Oncol; 2005 Feb; 10(1):51-7. PubMed ID: 15729602
    [TBL] [Abstract][Full Text] [Related]  

  • 28. On prejudice and facts and choices.
    Köhne CH; Folprecht G
    Ann Oncol; 2006 Feb; 17(2):185-7. PubMed ID: 16428244
    [No Abstract]   [Full Text] [Related]  

  • 29. Oral fluoropyrimidines in cancer treatment.
    Lewis NL; Meropol NJ
    Cancer Invest; 2000; 18(8):747-60. PubMed ID: 11107445
    [No Abstract]   [Full Text] [Related]  

  • 30. Plasma disposition of capecitabine and its metabolites 5'DFCR and 5'DFUR in a standard and dose-intensified monotherapy regimen.
    Czejka M; Schueller J; Farkouh A; Gruenberger B; Scheithauer W
    Cancer Chemother Pharmacol; 2011 Mar; 67(3):613-9. PubMed ID: 20495919
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Capecitabine dosing is not yet optimized for breast cancer.
    Hudis C; Traina T; Norton L
    Ann Oncol; 2010 Nov; 21(11):2291; author reply 2291-2. PubMed ID: 20501505
    [No Abstract]   [Full Text] [Related]  

  • 32. Management of carcinoma of the skin in solid organ transplant recipients with oral capecitabine.
    Endrizzi BT; Lee PK
    Dermatol Surg; 2009 Oct; 35(10):1567-72. PubMed ID: 19681993
    [No Abstract]   [Full Text] [Related]  

  • 33. Capecitabine in gastric cancer.
    Okines A; Chau I; Cunningham D
    Drugs Today (Barc); 2008 Aug; 44(8):629-40. PubMed ID: 18846273
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical pharmacokinetics of capecitabine.
    Reigner B; Blesch K; Weidekamm E
    Clin Pharmacokinet; 2001; 40(2):85-104. PubMed ID: 11286326
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incorporating oral capecitabine into the treatment of breast cancer. Introduction.
    Seidman AD; Aapro M
    Oncologist; 2002; 7 Suppl 6():1-3. PubMed ID: 12454313
    [No Abstract]   [Full Text] [Related]  

  • 36. Plasma disposition of capecitabine (CCB) and its metabolites 5'-deoxy-5-fluorocytidine (5'-DFCR) and 5'-deoxy-5-fluorouracil (5'-DFUR) with two different capecitabine/oxaliplatin dosage regimens.
    Farkouh A; Schueller J; Scheithauer W; Czejka M
    Int J Clin Pharmacol Ther; 2010 Jul; 48(7):487-8. PubMed ID: 20557855
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmacokinetic evaluation of capecitabine in breast cancer.
    Daniele G; Gallo M; Piccirillo MC; Giordano P; D'Alessio A; Del Giudice A; La Porta ML; Perrone F; Normanno N; De Luca A
    Expert Opin Drug Metab Toxicol; 2013 Feb; 9(2):225-35. PubMed ID: 23301520
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Capecitabine: effective oral fluoropyrimidine chemotherapy.
    McKendrick J; Coutsouvelis J
    Expert Opin Pharmacother; 2005 Jun; 6(7):1231-9. PubMed ID: 15957975
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early severe toxicities after capecitabine intake: possible implication of a cytidine deaminase extensive metabolizer profile.
    Mercier C; Dupuis C; Blesius A; Fanciullino R; Yang CG; Padovani L; Giacometti S; Frances N; Iliadis A; Duffaud F; Ciccolini J
    Cancer Chemother Pharmacol; 2009 May; 63(6):1177-80. PubMed ID: 19107485
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Capecitabine: the new generation of fluoropyrimidines in colorectal cancer.
    Iqbal S; Lenz HJ
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):947-55. PubMed ID: 15606325
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.